Percutaneous radiofrequency ablation for patients with malignant lung tumors: a phase II prospective multicenter study (JIVROSG-0702)

Hideo Gobara, Yasuaki Arai, Takeshi Kobayashi, Koichiro Yamakado, Yoshitaka Inaba, Yoshihisa Kodama, Takuji Yamagami, Miyuki Sone, Hirokazu Watanabe, Yoshihiro Okumura, Takayoshi Shinya, Hiroaki Kurihara, Susumu Kanazawa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: This prospective multicenter study aimed to evaluate the efficacy and safety of percutaneous radiofrequency (RF) ablation for lung cancer. Materials and methods: From May 2008 to April 2012, 33 patients (26 men, 7 women; mean age 70.5 years) were enrolled. RF ablation was performed using an internally cooled or expandable multitined electrode. The primary endpoint was complete response (CR) determined using 18F fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) performed 6 months after RF ablation. The secondary endpoint was the incidence and grade of adverse events (AEs) evaluated using the Common Toxicity Criteria for Adverse Events, version 3.0. Results: All patients underwent RF ablation and had efficacy analyses evaluated; however, FDG-PET/CT images before RF ablation were not available for two patients. The CR rate was 68 % (21 of 31 patients). One patient had a grade 5 AE unrelated to RF ablation. Grade ≥3 AEs occurred in 12 % of patients. During the follow-up period (median 37 months; range 1–55 months), five patients developed local tumor progression and nine (29 %) died. Overall survival at 1, 2, and 3 years was 97, 82, and 74 %, respectively. Conclusion: Percutaneous RF ablation is a safe, feasible, and effective treatment for small malignant lung tumors.

Original languageEnglish
Pages (from-to)556-563
Number of pages8
JournalJapanese Journal of Radiology
Volume34
Issue number8
DOIs
Publication statusPublished - Aug 1 2016

Fingerprint

Multicenter Studies
Prospective Studies
Lung
Neoplasms
Fluorodeoxyglucose F18
Lung Neoplasms
Electrodes
Safety
Survival
Incidence

Keywords

  • Clinical trial
  • JIVROSG
  • Lung cancer
  • Multicenter
  • Prospective
  • Radiofrequency ablation

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Percutaneous radiofrequency ablation for patients with malignant lung tumors : a phase II prospective multicenter study (JIVROSG-0702). / Gobara, Hideo; Arai, Yasuaki; Kobayashi, Takeshi; Yamakado, Koichiro; Inaba, Yoshitaka; Kodama, Yoshihisa; Yamagami, Takuji; Sone, Miyuki; Watanabe, Hirokazu; Okumura, Yoshihiro; Shinya, Takayoshi; Kurihara, Hiroaki; Kanazawa, Susumu.

In: Japanese Journal of Radiology, Vol. 34, No. 8, 01.08.2016, p. 556-563.

Research output: Contribution to journalArticle

Gobara, H, Arai, Y, Kobayashi, T, Yamakado, K, Inaba, Y, Kodama, Y, Yamagami, T, Sone, M, Watanabe, H, Okumura, Y, Shinya, T, Kurihara, H & Kanazawa, S 2016, 'Percutaneous radiofrequency ablation for patients with malignant lung tumors: a phase II prospective multicenter study (JIVROSG-0702)', Japanese Journal of Radiology, vol. 34, no. 8, pp. 556-563. https://doi.org/10.1007/s11604-016-0557-z
Gobara, Hideo ; Arai, Yasuaki ; Kobayashi, Takeshi ; Yamakado, Koichiro ; Inaba, Yoshitaka ; Kodama, Yoshihisa ; Yamagami, Takuji ; Sone, Miyuki ; Watanabe, Hirokazu ; Okumura, Yoshihiro ; Shinya, Takayoshi ; Kurihara, Hiroaki ; Kanazawa, Susumu. / Percutaneous radiofrequency ablation for patients with malignant lung tumors : a phase II prospective multicenter study (JIVROSG-0702). In: Japanese Journal of Radiology. 2016 ; Vol. 34, No. 8. pp. 556-563.
@article{160748eab61e4f31b08067078cfb02f7,
title = "Percutaneous radiofrequency ablation for patients with malignant lung tumors: a phase II prospective multicenter study (JIVROSG-0702)",
abstract = "Purpose: This prospective multicenter study aimed to evaluate the efficacy and safety of percutaneous radiofrequency (RF) ablation for lung cancer. Materials and methods: From May 2008 to April 2012, 33 patients (26 men, 7 women; mean age 70.5 years) were enrolled. RF ablation was performed using an internally cooled or expandable multitined electrode. The primary endpoint was complete response (CR) determined using 18F fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) performed 6 months after RF ablation. The secondary endpoint was the incidence and grade of adverse events (AEs) evaluated using the Common Toxicity Criteria for Adverse Events, version 3.0. Results: All patients underwent RF ablation and had efficacy analyses evaluated; however, FDG-PET/CT images before RF ablation were not available for two patients. The CR rate was 68 {\%} (21 of 31 patients). One patient had a grade 5 AE unrelated to RF ablation. Grade ≥3 AEs occurred in 12 {\%} of patients. During the follow-up period (median 37 months; range 1–55 months), five patients developed local tumor progression and nine (29 {\%}) died. Overall survival at 1, 2, and 3 years was 97, 82, and 74 {\%}, respectively. Conclusion: Percutaneous RF ablation is a safe, feasible, and effective treatment for small malignant lung tumors.",
keywords = "Clinical trial, JIVROSG, Lung cancer, Multicenter, Prospective, Radiofrequency ablation",
author = "Hideo Gobara and Yasuaki Arai and Takeshi Kobayashi and Koichiro Yamakado and Yoshitaka Inaba and Yoshihisa Kodama and Takuji Yamagami and Miyuki Sone and Hirokazu Watanabe and Yoshihiro Okumura and Takayoshi Shinya and Hiroaki Kurihara and Susumu Kanazawa",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s11604-016-0557-z",
language = "English",
volume = "34",
pages = "556--563",
journal = "Japanese Journal of Radiology",
issn = "1867-1071",
publisher = "Springer Japan",
number = "8",

}

TY - JOUR

T1 - Percutaneous radiofrequency ablation for patients with malignant lung tumors

T2 - a phase II prospective multicenter study (JIVROSG-0702)

AU - Gobara, Hideo

AU - Arai, Yasuaki

AU - Kobayashi, Takeshi

AU - Yamakado, Koichiro

AU - Inaba, Yoshitaka

AU - Kodama, Yoshihisa

AU - Yamagami, Takuji

AU - Sone, Miyuki

AU - Watanabe, Hirokazu

AU - Okumura, Yoshihiro

AU - Shinya, Takayoshi

AU - Kurihara, Hiroaki

AU - Kanazawa, Susumu

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Purpose: This prospective multicenter study aimed to evaluate the efficacy and safety of percutaneous radiofrequency (RF) ablation for lung cancer. Materials and methods: From May 2008 to April 2012, 33 patients (26 men, 7 women; mean age 70.5 years) were enrolled. RF ablation was performed using an internally cooled or expandable multitined electrode. The primary endpoint was complete response (CR) determined using 18F fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) performed 6 months after RF ablation. The secondary endpoint was the incidence and grade of adverse events (AEs) evaluated using the Common Toxicity Criteria for Adverse Events, version 3.0. Results: All patients underwent RF ablation and had efficacy analyses evaluated; however, FDG-PET/CT images before RF ablation were not available for two patients. The CR rate was 68 % (21 of 31 patients). One patient had a grade 5 AE unrelated to RF ablation. Grade ≥3 AEs occurred in 12 % of patients. During the follow-up period (median 37 months; range 1–55 months), five patients developed local tumor progression and nine (29 %) died. Overall survival at 1, 2, and 3 years was 97, 82, and 74 %, respectively. Conclusion: Percutaneous RF ablation is a safe, feasible, and effective treatment for small malignant lung tumors.

AB - Purpose: This prospective multicenter study aimed to evaluate the efficacy and safety of percutaneous radiofrequency (RF) ablation for lung cancer. Materials and methods: From May 2008 to April 2012, 33 patients (26 men, 7 women; mean age 70.5 years) were enrolled. RF ablation was performed using an internally cooled or expandable multitined electrode. The primary endpoint was complete response (CR) determined using 18F fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) performed 6 months after RF ablation. The secondary endpoint was the incidence and grade of adverse events (AEs) evaluated using the Common Toxicity Criteria for Adverse Events, version 3.0. Results: All patients underwent RF ablation and had efficacy analyses evaluated; however, FDG-PET/CT images before RF ablation were not available for two patients. The CR rate was 68 % (21 of 31 patients). One patient had a grade 5 AE unrelated to RF ablation. Grade ≥3 AEs occurred in 12 % of patients. During the follow-up period (median 37 months; range 1–55 months), five patients developed local tumor progression and nine (29 %) died. Overall survival at 1, 2, and 3 years was 97, 82, and 74 %, respectively. Conclusion: Percutaneous RF ablation is a safe, feasible, and effective treatment for small malignant lung tumors.

KW - Clinical trial

KW - JIVROSG

KW - Lung cancer

KW - Multicenter

KW - Prospective

KW - Radiofrequency ablation

UR - http://www.scopus.com/inward/record.url?scp=84980316441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980316441&partnerID=8YFLogxK

U2 - 10.1007/s11604-016-0557-z

DO - 10.1007/s11604-016-0557-z

M3 - Article

C2 - 27260478

AN - SCOPUS:84980316441

VL - 34

SP - 556

EP - 563

JO - Japanese Journal of Radiology

JF - Japanese Journal of Radiology

SN - 1867-1071

IS - 8

ER -